Study of serplulimab with chemo before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests if adding serplulimab to standard chemotherapy before surgery can help shrink locally advanced stomach or gastroesophageal junction cancer. It aims to improve treatment outcomes for patients who are candidates for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach cancer or cancer where the stomach meets the esophagus (Siewert type II or III) that has spread to nearby lymph nodes but not to distant organs.
- Your cancer is at a stage where surgery is planned after chemotherapy.
- You have not had chemotherapy, radiation, or immunotherapy before.
- Your liver, kidneys, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
This Phase 2 trial tests whether adding a PD-1 antibody (JS001/toripalimab) to chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction adenocarcinoma. It aims to help shrink the tumor and make surgery more effective.
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.